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Abstract
The promise of cellular therapy lies in healing damaged tissues and organs in vivo as well as 
generating tissue constructs in vitro for subsequent transplantation. Adult stem cells are ideally 
suited for cellular therapies due to their pulripotency and the ease with which they can be cultured 
on novel functionalized substrates. Creating environments to control and successively driving their 
differentiation toward a lineage of choice is one of the most important challenges of current cell-
based engineering strategies. In recent years, a variety of biomedical platforms have been prepared 
for stem cell cultures, primarily to provide efficient delivery of growth or survival factors to cells 
and a conducive microenvironment for their growth. Here, we demonstrate that repeating 
tetralayer structures composed of biocompatible poly(methacrylic acid) (PMAA)/poly(acryl 
amide) (PAAm)/poly(methacrylic acid) (PMAA)/poly(ethylene oxide)-block-poly(ε-caprolactone) 
(PEO-b-PCL) micelles arrayed in layer-by-layer (LbL) films can serve as a payload region for 
dexamethasone (dex) delivery to human mesenchymal stem cells (MSCs). This architecture can 
induce MSC differentiation into osteoblasts in a dose-dependent manner. The amount of dex 
loaded in the films is controlled by varying the deposition conditions and the film thickness. 
Furthermore, release of dex is also controlled by changing the amount of covalent crosslinking of 
multilayers via thermal treatments. The multilayer architecture including payload and cell-
adhesion region introduced here are well suited for extended cell culture thus affording the 
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important and protective effect of both dex release and immobilization. These films may find 
applications in the local delivery of immobilized therapeutics for biomedical applications, as they 
can be deposited on a wide range of substrates with different shapes, sizes, and composition.
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1. Introduction
Surface coatings incorporating therapeutic molecules have recently begun to play an 
important role in the design of biomedical devices, implantable biomaterials, industrial 
bioprocesses and engineered biological interfaces.1–7 A promising strategy to develop such a 
biomedical platform is by creating multi-functional polymer coatings that can safely 
encapsulate and release sensitive biological molecules in an active form within multilayer 
architectures for controlled release directly from film surfaces.8–14
Layer-by-layer (LbL) deposition has been widely used to fabricate multilayer architectures 
by complementary interactions between components, such as positively and negatively 
charged materials15–16 or materials that have hydrogen bond donor and acceptor 
groups,17–18 where each layer is adsorbed sequentially onto a surface to achieve a film. Due 
to a growing interest in applying multilayer architectures to biomedical applications, 
erodible multilayers that degrade in a controlled manner via disassembly are being explored 
as a potential platform for controlled release drug delivery over extended time periods. 
Automated LbL deposition methods are advantageous in that the films are prepared under 
mild aqueous conditions that preserve drug bioactivity. Furthermore, incorporation of 
various therapeutics into multilayers for systematic release has been studied from small-
molecule steroids and antibiotics to macromolecules such as protein therapeutics, active 
proteins, enzymes, nucleic acids and plasmid DNA.19–27 Multilayers can be conformally 
coated onto substrates with simple and complex geometries to load therapeutics and to 
control the release of these over a defined time period. More recently, multilayer thin films 
have been developed to permit the release of drug dosages with desired periods of time 
ranging from minutes to days. Thus, there is tremendous potential to use these 
polyelectrolyte films as cell differentiation platforms. Multilayer thin films are well suited 
for this application due to the flexibility these structures afford in terms of biocompatibility, 
material properties, cost of application, and the ability to finely tune surface characteristics 
as desired. The ability to achieve precise and extended-term drug delivery will enable a 
broader set of clinical applications where precision dosing must occur over longer time 
spans.28–32
Human mesenchymal stem cells, also known as multipotent stromal cells (MSCs) are adult 
progenitors that maintain the potential to differentiate into numerous cell types found within 
adult connective tissues. A wide range of functionally, morphologically, and 
transcriptionally distinct phenotypes have been derived from a common MSC precursor. 
This intrinsic multipotent property, coupled with the ability to isolate large quantities of 
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these cells from the bone marrow, highlights the potential of MSCs as a cell source for 
regenerative medical applications.33–36 MSCs are influenced by their physical micro-
environment (stiffness and geometry), as well as by biochemical cues from small molecules, 
and exogenous, paracrine, and autocrine signaling. The utility of thin film multilayer 
surfaces derives from the ability to influence all aspects of the MSC niche. Tuning of 
surface features, and delivery of biochemical signals in the form of small molecules are both 
possible using this approach.
In this work, we present a simple strategy to prepare functional surfaces with tunable and 
durable biological activity by taking advantage of LbL assembled multilayer thin films with 
embedded small bio-active molecules to guide MSC differentiation. To safely encapsulate 
drugs, polymeric micelles are introduced into LbL films. Specifically, we have constructed 
LbL films of repeating tetralayer structures composed of biocompatible poly(acryl amide) 
(PAAm), poly(methacrylic acid) (PMAA), and poly(ethylene oxide)-block-poly(ε-
caprolactone) (PEO-b-PCL) micelles. In this (PMAA/PAAm/PMAA/PEO-b-PCL)n (n = 
number of tetralayers) architecture, both electrostatic interaction between PMAA/PAAm, 
and hydrogen bonding between PMAA/PEO-b-PCL were employed to build multilayers. 
We demonstrate that the resulting films degrade in a repeatable and predictable manner to 
release drug-loaded micelles into the surrounding cell culture medium under physiological 
conditions. Furthermore, we are able to tailor the rate of film degradation to control the rate 
of drug release by varying the degree of covalent anhydride crosslinking between carboxylic 
acid groups in PMAA thus slowing degradation to the desired rate. Since micelle 
incorporation into multilayer thin films and encapsulation of drugs into micelles do not 
require specific chemical modifications during the fabrication process, and introducing 
further crosslinking permits control over the release profile of drugs, this approach is 
particularly well suited for incorporating active hydrophobic therapeutics for various 
biological and biomedical coatings.
2. Experimental Section
Materials
Poly(methacrylic acid) (PMAA, Mw 15,000 30% aqueous solution) and Poly(acryl amide) 
(PAAm, Mw 5,000,000 1% aqueous solution) were obtained from Polysciences Inc. 
(Warrington, PA). Amphiphilic block copolymer, poly(ethylene oxide)-block-poly(ε-
caprolactone) (PEO-b-PCL, Mn (PEO) 5000, Mn (PCL) 6500, PDI 1.3) was purchased from 
Polymer Source (Montreal, Canada). poly(diallyldimethyl ammonium chloride) (PDAC, 
Mw = 200,000–350,000 g/mol), and poly(sodium 4-styrenesulfonate) (PSS, Mw = 70,000) 
were purchased from Aldrich. poly(diallyldimethyl ammonium chloride) (PDAC, Mw = 
200,000–350,000 g/mol), and poly(sodium 4-styrenesulfonate) (PSS, Mw = 70,000) were 
purchased from Aldrich. Sodium hyaluronate (or hyaluronic acid (HA), Mn = 1.76 MDa) 
was purchased from Lifecore Biomedical, Inc. (Chaska, MN) Collagen I from rat-tail, 
Collagen I from calf skin, Collagen IV from human placenta, and Dexamethasone (dex) 
were obtained from Sigma. All other reagents and solvents were purchased from Aldrich 
and used as received. Quartz slide, silicon wafer, Teflon, and polypropylene were used as 
substrates for the LbL assembly and cleaned extensively prior to the deposition.
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Block Copolymer Micelle Formation
Block copolymer micelles of PEO-b-PCL were prepared according to a modification of a 
previously published method. Briefly, a stock solution of PEO-b-PCL was freshly prepared 
in tetrahydrofuran (THF) at a concentration of 10 mg/mL. Then, 200 mL of stock solution 
was placed in a vial with gentle stirring. To this solution was gradually added 5.0 mL of 
Millipore water (18 M·cm) with vigorous stirring. After an additional 1 h of stirring, the 
resulting suspension was subjected to dialysis against Millipore water for over 24 h 
(Spectra/Por 4 regenerated cellulose membrane, MWCO 12,000–14,000) to remove any 
residual solvent. The resulting PEO-b-PCL micelle was filtered prior to use. The pH of the 
resulting micelle suspension was adjusted with 0.10 M HCl solution right before LbL film 
formation. For dex loading, we followed a modification of previously published protocol. 
Briefly, dex solution in THF (concentration 1.0 mg/mL) was dropwise added to 5.0 mL of 
the micelle suspension prepared above (0.40 mg/mL). The emulsion was vigorously stirred 
overnight with a loose cap to evaporate the organic solvent. The solution obtained was 
centrifuged (4500 rpm, 10 min) and filtered through a 0.45 m syringe filter. The drug 
content in a micelle was evaluated by measuring the characteristic absorbance of dex in a 
solvent mixture of MeOH and H2O (9:1 v/v), employing a calibration curve with a known 
concentration of Dexamethasone using an Agilent 8453 UV–Visible spectrometer.
Layer-by-Layer (LbL) Film Assembly
All LbL films were assembled with a modified programmable Carl Zeiss HMS slide stainer. 
Typically, films were constructed on various substrates with approximate size of 1 ~ 2 in2. 
The O2-plasma-treated substrate was first dipped into PMAA aqueous solution (10 mM, pH 
3) for 10 min and rinsed three times with water (pH 3) for 1 min each. Subsequently, the 
substrate was introduced into aqueous solution of PAAm (10 mM, pH 3), PMAA aqueous 
solution (10 mM, pH 3) and PEO-b-PCL micelle solution (0.40 mg/mL, pH 3) for 10 min 
and washed again three times with water (pH 3) for 1 min each. This cycle provides one 
tetralayer of PMAA, PAAm, PMAA and PEO-b-PCL micelle, denoted (PMAA/PAAm/
PMAA/PEO-b-PCL). The dipping process was repeated until the desired number of bilayers 
was obtained. Cell adhesion region was prepared by spin-LbL deposition (2500 rpm, 30 
sec).
Surface Morphology
The surface morphology of BCM multilayer films was investigated by field emission 
scanning electron microscopy (XL30FEG, Philips)
Measurement of Film Thickness
Following deposition, films were immediately removed from the final rinsing bath and 
nitrogen-dried. Film thickness was determined either by ellipsometry at ten different 
predetermined locations on the film surface or by profilometry at three different scratch 
sites.
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The UV-Vis spectra were obtained using a Perkin Elmer Lambda UV-vis spectrometer. 
Dexamethasone showed the absorbance peak centered at 238 nm.
Cell Culture
All MSCs used in this work were passage three human bone marrow derived mesenchymal 
stromal cells. Passage two human MSCs were obtained from the Texas A&M Health 
Sciences Center and expanded one additional passage before each experiment. Cellular 
differentiation assays to confirm osteogenic, chondrogenic, and adipogenic potential are 
performed at Texas A&M Health Science Center. Cells were expanded in Dulbecco’s 
Modified Eagle’s Medium supplemented with 16.5% fetal calf serum, 4.5 g/L glucose, L-
glutamine, sodium pyruvate, non-essential amino acids, and penicillin/streptomycin at 37 °C 
and 5% CO2. All experiments were conducted using cells derived from the same patient lot.
Alkaline phosphatase Activity Assay
Alkaline phosphatase activity was measured using the colorimetric substrate para-
nitrophenylphosphate which develops a yellow end product readable at 405 nm (pNPP ALP 
Kit, Sigma Aldrich). Samples were incubated at room temperature for 60 minutes then 
stopped with 2 N NaOH. Standard curves were generated using dilutions of p-nitrophenol. 
Activity was normalized to total protein content as measured by BCA assay (Pierce).
Quantitative Real Time PCR (qRT-PCR)
RNA extracts were prepared using the Qiagen RNeasy kit. Samples were normalized to 500 
ng total RNA content prior to qRT-PCR cycling. All biological replicates were aliquoted 
into three technical replicates. Primers and OneStep qRT-PCR kit were from Qiagen. 
Realtime optical readings were performed using the Chromas 4 system. Abundance levels 
for each gene (A) of interest were calculated from the take-off cycle (Ct) and efficiency (E) 
for each gene using: A=1/(1+E)Ct. All sample abundances were normalized to GAPDH 
abundance for each experimental condition.
3. Results and Discussion
To develop a polyelectrolyte multilayer film with controllable drug loading and release 
properties, we created three functional regions (Figure 1a). First, an base layer was prepared 
directly onto the substrate to mitigate substrate effects on binding by precoating a planar 
silicon wafer or glass slide with ten and a half bilayers of poly(diallyldimethyl ammonium 
chloride) (PDAC) and poly(sodium 4-styrenesulfonate) (PSS) as a nondegradable layers (ca. 
67 nm thick) to ensure the presence of uniform surface charge for the deposition. Next, the 
payload region holding the nano-container with drugs was fabricated. Dexamethasone (dex) 
is a synthetic glucocorticoid that can induce early commitment along an osteogenic lineage 
when applied to MSCs.37–39 Dex was encapsulted within PEO-b-PCL micelles and 
assembled into multilayer thin films. The dex containing PEO-b-PCL (PEO-b-PCLdex) 
micelles had a hydrodynamic diameter of 98.8 ± 13.4 nm in solution, measured by dynamic 
light scattering (DLS). The payload region consisted of twenty tetralayers of electrostatically 
and hydrogen-bonded PMAA/PAAm/PMAA/PEO-b-PCLdex and was terminated with a 
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three and half PMAA/PAAm layers. The advantages of this tetralayer (i.e., (PMAA/PAAm/
PMAA/PEO-b-PCL) are: (1) even distribution of dex in payload region, (2) ability to 
generate amide and anhydride bonds with thermal treatment to control the film crosslinking 
density of the tetralayer, and (3) the ability to easily control the amount of dex incorporated. 
The topmost region of the film was cell adhesive prepared by collagen, polysaccharide and 
disaccharide to promote cell adhesion at top of multilayer film (Figure 1a).
The dex absorbance peak at 238 nm was monitored as the (PMAA/PAAm/PMAA/PEO-b-
PCLdex)n films were assembled. The absorbance at 238 nm grows linearly with increasing 
tetralayer numbers of (PMAA/PAAm/PMAA/PEO-b-PCLdex) (Figure 1(b)) demonstrating 
the linear film growth. The average thickness per tetralayer was 67.1 ± 6.8 nm. Covalent 
crosslinking in the LbL films was achieved through heat treatment at 150 °C under vacuum 
for up to 12 hours. Figure 1c is the FT-IR spectrum of the heat-treated (PMAA/PAAm/
PMAA/PEO-b-PCLdex)20(PMAA/PAAm)3.5 payload region with respect to time. New 
peaks at 1042 cm−1 and 1804 cm−1 appeared after heat treatment which are attributed to 
anhydride bond formation by PMAA-PAAm (Amide), PMAA-PMAA (anhydride) and 
PAAm-PAAm (imide bonds) form through a condensation process. However the peaks for 
amide, anhydride and imide bonds overlap as indicated by the asymmetric and symmetric 
signatures of C=O in PEO-b-PCL (1780−1 to 1660m−1). Therefore covalent bonded 
crosslinking derived from heat treatment were indirectly confirmed through the formation of 
anhydride peaks (i.e., 1042 cm−1 and 1804 cm−1). The average film thickness of the payload 
region before heat treatment was 1432 ± 87 nm while after treatment it decreased to 1227 ± 
15 nm, a reduction of about 7%. It is well known that hydrogen-bonded self-assembled 
multilayers can be easily disrupted by thermal means. However, heating the multilayer film 
at 150 °C for 12 hour introduces chemical crosslinks that stabilize the multilayer assembly 
even at pH 7.4 in phosphate buffer saline (PBS) buffer. The heated multilayer film 
experiences an 8.5% film thickness reduction after heat treatment after 60 hours of 
immersion in PBS solution. Cross linking the film for 3 hours, on the other hand, does not 
enhance the film resistance to the PBS buffer to a large extent, possibly due to the low 
degree of an-hydride linkage formation. Films that are not crosslinked by heat treatment 
dissolve immediately when immersed in PBS.
A cell adhesive region was introduced onto the payload region to control MSCs adhesion 
For which various materials were examined. Positively charged Collagen I (Most abundant 
form of collagen) from rat tail, Collagen III from calf skin, and Collagen IV (Most 
interstitial tissues) from human placenta, as well as negative charged hyaluronic acid (HA), 
heparin (HEP), Poly(methacrylic acid) (PMAA) and Poly(acrylic acid) (PAA). Triple helix-
rich fragments of collagen are well known adhesion substrate to cells and HA is a highly 
attractive natural biomaterial due to its role in the extracellular matrix,40 and its influence on 
cell behavior.41 Heparin, a highly-sulfated glycosaminoglycan, is widely used as an 
injectable anticoagulant, and has the highest negative charge density of any known 
biological molecule.42–43 PMAA and PAA are also well known biodegradable, 
biocompatible polyelectrolytes.44–45 Multilayer films with each of these biomaterials were 
used to fabricate the four and half bilayer top surface for cell adhesion and were screened for 
suitability (see supporting information S1). We examined the effect of the various top-level 
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materials on initial cell adhesion. Phase-contrast micrographs were taken 24h after MSC 
seeding in MSC growth media at densities optimum for differentiation. After 24h, the cell 
adhesion region appeared to have a negligible effect on initial cell adhesion and spreading 
on each combination. Among the combinations, multilayers prepared with PMAA and PAA 
spontaneously peeled off in PBS buffer, which is not suitable for cell adhesion. Cell 
adhesive layers of other combinations of materials (i.e., Collagen I and III multilayered with 
HA and Heparin) exhibited higher cell density and better stability in solution. In this 
manuscript, 112 ± 19 nm of the 4.5 bilayer of collagen I/HA cell adhesive region was 
selected for further experiments.
The surface morphology of both payload and cell-adhesion region were observed by SEM 
(Figure 2). Dex encapsulated PEO-b-PCL micelles remain distinguishable on the surface 
with high roughness resulting from the swell and coalescence that occur during the LbL 
assembly process as shown in Figure 2(a). After coating the 4.5 bilayers of collagen I/HA 
multilayer onto the payload region, we observed uniform and dense morphology consistent 
with micro/nano structures (Figure 2(b)).
Dex release experiments were performed by immersing a substrate in a sealed vial 
containing 3 ml of buffered solution. At indicated time points, films were removed and re-
immersed into appropriate buffer solution. Figure 3(a) shows the change in payload/cell 
adhesive region multilayer film thickness with time following immersion in PBS solution. 
The thickness of the portions of film remaining on the surface was determined to decrease 
linearly with respect to time of exposure to PBS over a 3 min time period. All films with 
different crosslinking densities demonstrate both dissolving and swelling during the 
submersion. Following a brief swelling period, hydrolysis emerges as the dominant factor 
affecting film thickness. In all cases, film thickness decreases at a constant rate: 
approximately 438, 433.6, 7.47, 3.63 and 1.88 nm/hour for 0, 3, 6, 9 and 12 hour heat 
treatment-based conditions, respectively.
Finally, to examine the potential of a drug payload region as a platform for hydrophobic 
therapeutic delivery the release profiles of dex were evaluated by measuring the dex release 
from the payload region after incubation in a model physiological solution (PBS buffer, 37 
°C, 5% CO2). Dex was released over a course of two hours from untreated multilayer films, 
whereas the cross-linked film exhibited a significantly longer release up to 72 hours for a 6 
hour thermally cross-linked film and 290 hours for 12 hours for thermally cross-linked films 
(Figure 3). This is a unique feature of the hydrogen bonded system, for which simple post-
modification to introduce internal cross-links within the LbL film enables the control of the 
release kinetics of active small, hydrophobic therapeutics from 3 hours up to 290 hours. We 
expect that this fine control over the release profile will be highly advantageous for potential 
use in biological applications that require a controllable release of hydrophobic active 
therapeutics. For example, untreated, non-cross-linked films would be interesting for wound 
dressings and therapeutic surface coatings, where an immediate delivery of therapeutics is 
necessary upon contact with the film. In contrast, cross-linked film would be useful as a 
carrier for active therapeutics on biomaterial surfaces for an extended period of time such as 
with surgical implant materials.
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To assess the ability of dex loaded thin film multilayers to exert a biological effect we 
examined the expression of early osteogenic markers in MSCs cultured on multilayers 
which produce a controlled dex release over extended times. Cells were cultured for 14 days 
on three different kinds of multilayer films including cell adhesive region only (Figure 4(a)), 
payload-without dex/cell adhesive region (Figure 4(b)) and payload-with dex/cell adhesive 
region (Figure 4(c)) with a dex release profile matching the longest release time. As shown 
in figure 4(d), MSCs cultured on dex releasing surfaces exhibited a two-fold increase in 
alkaline phosphatase activity when compared with MSCs cultured on control surfaces with 
no dex payload. Likewise, mRNA for later markers of osteogenic differentiation such as 
osteopontin and osteocalcin were upregulated by 1.5 fold and 20 fold, respectively, when 
compared with control cultures, as indicated by quantitative real time PCR in figure 4(e). 
The ability of thin films with a dex payload to induce early and mid-point osteoenic markers 
in MSCs is indicative of the utility of these surfaces to bring about real biological effects 
over time spans that are therapeutically relevant. The induction of osteogenic markers in 
MSCs using only expansion medium and under conditions which derive osteogenic simtuli 
only from the payload release and cell adhesive properties of the thin film substrate is a clear 
demonstration of the potential of this approach.
4. Conclusion
We have demonstrated a simple, tunable drug release thin film multilayer platform that is 
capable of producing significant biological effects over extended time periods. Using our 
approach we demonstrated early osteogenic differentiation of mesesenchymal stem cells 
induced through controlled release of dex from a payload region as well as from surface 
adhesion cues. The simplicity of this design is attributable to the few functional layers 
required: a substrate base layer, a payload region and a cell adhesion region. The best 
performing construct incorporating these layers consisted of (PMAA/PAAm/PMAA/PEO-b-
PCLdex)20(PMAA/PAAm)3.5 and (Collagen I/HA)4.5 which exhibited highly tunable release 
profiles to complement surface cues from Collagen I and HA. The ability to tune drug 
release and surface properties to this extent opens additional applications of LbL technology 
to challenging problems in regenerative medicine.
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(a) The schematic illustration of the thin film multilayer platform. (b) UV-Vis spectra of 
(PMAA/PAAm/PMAA/PEO-b-PCLdex)20 multilayer film as a function of tetralayer 
number. The absorption peak at 238 nm originates from dex in PEO-b-PCL micelles. (c) FT-
IR absorbance spectra of multilayer films with different heat treatment times.
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SEM images of (a) substrate/(PDAC/PSS)10.5(PMAA/PAAm/PMAA/PEO-b-
PCLdex)20(PMAA/PAAm)3.5 and (b) substrate/(PDAC/PSS)10.5(PMAA/PAAm/PMAA/
PEO-b-PCLdex)20 (PMAA/PAAm)3.5 (Collagen I/ HA)4.5
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(a) Film thickness as a function of release time following immersion in PBS at pH 7.4. Error 
bars represent the standard deviation of measured thickness values. (b) Cumulative 
normalized kinetics of dex release from platform immersed in PBS (pH 7.4 at 37 °C), for 
films prepared with different crosslinking density by heat treatment. In both (a) and (b) 
platforms include payload and cell adhesive regions.
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Brightfield micrographs of MSCs after 14 days on (a) Glass/(PDAC/PSS)10.5(Collagen 
I/HA)4.5 (b) Glass/(PDAC/PSS)10.5(PMAA/PAAm/PMAA/PEO-b-PCL)20(PMAA/
PAAm)3.5 (Collagen I/HA)4.5 and (c) Glass/(PDAC/PSS)10.5(PMAA/PAAm/PMAA/PEO-
b-PCLdex)20(PMAA/PAAm)3.5(Collagen I/ HA)4.5. (d) Alkaline Phosphatase activity on day 
7 under the three culture conditions shown (n = 3, replicates, +/− s.d., *p<0.01) (e) Fold 
change in gene expression levels of the genes shown on day 10 (n = 3, replicates, +/− s.d., 
*p<0.05).
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